Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| AAPC | Average annual percent change |
| ADR | Adverse drug reaction |
| AE | Adverse event |
| AHFS | American Hospital Formulary Service |
| AKT | Protein kinase B |
| ASCT | Autologous stem cell transplantation |
| ATC | Anatomical Therapeutic Chemical |
| AUC | Area under the concentration-time curve |
| BOR | Best overall response |
| BTK | Bruton tyrosine kinase |
| CAR-T | Chimeric antigen receptor T-cell |
| CAS | Chemical Abstracts Service |
| CD79B | Cluster of differentiation 79B |
| CI | Confidence interval |
| CLL | Chronic lymphocytic leukemia |
| CNS | Central nervous system |
| CR | Complete response |
| CRu | Unconfirmed complete response |
| CSF | Cerebrospinal fluid |
| CYP | Cytochrome P450 |
| DLBCL | Diffuse large B-cell lymphoma |
| DOR | Duration of response |
| EANO | European Association of Neuro-Oncology |
| ECOG | Eastern Cooperative Oncology Group |
| EHA | European Hematology Association |
| EORTC | European Organisation for Research and Treatment of Cancer |
| EQ-5D | EuroQol five-dimension questionnaire |
| ERK | Extracellular signal-regulated kinase |
| ESMO | European Society for Medical Oncology |
| FDA | Food and Drug Administration |
| HDC | High-dose chemotherapy |
| HD-MTX | High-dose methotrexate |
| HRQoL | Health-related quality of life |
| ILD | Interstitial lung disease |
| IPCG | International Primary CNS Lymphoma Collaborative Group |
| IRC | Independent review committee |
| JCOG | Japan Clinical Oncology Group |
| JPY | Japanese yen |
| KPS | Karnofsky Performance Status |
| MCL | Mantle cell lymphoma |
| MRI | Magnetic resonance imaging |
| MTR | Methotrexate, temozolomide, and rituximab |
| MTX | Methotrexate |
| MYD88 | Myeloid differentiation primary response 88 |
| NDA | New drug application |
| ORR | Overall response rate |
| OS | Overall survival |
| P-gp | P-glycoprotein |
| PBC | Primary biliary cholangitis |
| PCNSL | Primary central nervous system lymphoma |
| PDUFA | Prescription Drug User Fee Act |
| PFS | Progression-free survival |
| PK | Pharmacokinetics |
| PMDA | Pharmaceuticals and Medical Devices Agency |
| PR | Partial response |
| QoL | Quality of life |
| R-MPV | Rituximab, methotrexate, procarbazine, and vincristine |
| R/R | Relapsed or refractory |
| rwPFS | Real-world progression-free survival |
| SD | Stable disease |
| SJS | Stevens-Johnson syndrome |
| TEAE | Treatment-emergent adverse event |
| TEN | Toxic epidermal necrolysis |
| TIR | Tirabrutinib |
| TRAE | Treatment-related adverse event |
| TWD | New Taiwan dollar |
| USD | United States dollar |
| WBRT | Whole-brain radiotherapy |
| WM | Waldenström macroglobulinemia |